- Advertisement -
Announced today, Melbourne-based biotech Telix Pharmaceuticals (ASX: TLX) is a step closer to launching its prostate cancer diagnostic agent Illuccix in Europe after securing authorisation for its commercial distribution.
The company announced it received a positive decision on its Marketing…
